Regeneron Receives FDA Approval for Gene Therapy Treating Genetic Hearing Loss
Regeneron (REGN) received accelerated approval from the U.S. Food and Drug Administration (FDA) for Otarmeni, a groundbreaking gene therapy targeting OTOF-related hearing loss. This marks the first approved gene therapy for genetic deafness. The company plans to offer the treatment free of charge in the U.S., which may raise questions about its financial strategy but highlights Regeneron's leadership and innovation.
Tickers: $REGN